胰激肽原酶治疗糖尿病肾病疗效的系统评价

Clinical efficacy of Kininogenase in the treatment of diabetic nephropathy: a systematic evaluation

目的评价胰激肽原酶治疗糖尿病肾病的疗效。方法通过检索近二十年PubMed、Science Direct、EBSCO Host、EMbase、The Cochrane Library、中国学术期刊全文数据库、万方数据库、维普中文科技期刊全文数据库,对纳入研究的方法学进行评价。研究者对纳入文献的质量进行严格评价和资料提取,使用Review manager 5.0软件对符合质量标准的RCTs行系统评价。结果 12个RCT共纳入762例患者,其中治疗组389例,对照组373例,系统评价结果显示,相比于血管紧张素Ⅱ受体拮抗剂、血管紧张素转化酶抑制剂、前列地尔,采用胰激肽原酶治疗糖尿病肾病,更能显著降低尿白蛋白排泄率,从而缓解糖尿病肾病的病理进程。结论胰激肽原酶可显著提升治疗糖尿病肾病的疗效,值得推广。

Objective To evaluate the clinical efficacy of Kininogenase in the treatment of diabetic nephrop- athy. Methods The methodology were evaluated based on references in the recent 20 years from PubMed, Science Direct, EBSCO Host, EMBASE, The Cochrane Library, CNKI, CECDB CQVIP. The researchers performed rigorous